The global fondaparinux market is expected to reach USD 686.3 million by
2024

Fondaparinux is majorly used during knee and hip replacement surgeries.
Arixtra, manufactured by GSK group of companies is the branded drug of
Fondaparinux. The drug witnessed patent expiry in 2002. As the active
molecule is highly complex to manufacture, it faced low generic
competition until 2011. Generic manufacturer companies, such as Alchemia
Ltd. and Apotex, Inc., received the Abbreviated New Drug Application
approval in 2011 and instantly started the production of generic drugs.

Fondaparinux is used as an anticoagulant and shows improved survival
compared with low-molecular-weight heparin. It is used for the
prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and
is administered subcutaneously. Moreover, Fondaparinux lowers the risk
of ischemic events

The increasing collaboration between the key players for acquiring the
Intellectual Property Rights (IPRs) in order to manufacture the molecule
through patented technology is expected to drive growth.

For instance, in July 2016 Dr. Reddy's Laboratories Ltd. entered into an
agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium
for USD 17.5 million. In September 2014, Mylan N.V. purchased branded
and generic versions of fondaparinux sodium from Aspen Global, Inc. for
USD 225 million.

The deal gave Mylan N.V. access to one of the two generics indicated for
the treatment of PE.

Further key Findings From the Study Suggest:

Generics and authorized generics of Arixtra (fondaparinux sodium)
dominated the market in 2015 with share of over 65.0%

The introduction of generic drugs in the market by Apotex, Inc., Dr.
Reddy's, and Mylan N.V. is expected to drive the market growth.

North America held the largest market share of the global market in
2015. Key factors attributing to the dominance include constantly
increasing geriatric population, rising prevalence of thrombosis, and
the introduction of low-cost generics of Fondaparinux in the U.S.

In addition, the increasing number of awareness initiatives undertaken
by government and nongovernment organizations for DVT and PE is
driving the growth of the market in the North American region.

China's huge population base with the rising disposable income coupled
with the increased burden of chronic diseases is expected to be one of
the major drivers for the Chinese market over the forecast period.

Moreover, the presence of local active pharmaceutical ingredients
manufacturers and contract research organizations in China increased
the number of foreign investments in the country. As a result, China
is estimated to grow at CAGR of 21.2% till 2024

Major companies identified in the market include Dr. Reddy's
Laboratories, Inc., GSK group of companies, Mylan N.V., and Alchemia
among others.

The Fondaparinux market is a consolidated market and is marked by the
presence of mergers and acquisitions